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 In the year 2011 a total of 219,075 new leprosy 
cases were registered in the world, of whom 127,295 
were in India1. Among the new cases detected in India, 
approximately 3 per cent have grade 2 disability, 
referring to the presence of visible (and often permanent) 
deformity. It has been estimated that in 2015 there will 
be nearly 500,000 people living in India with grade 2 
disability due to leprosy2. Leprosy affects the peripheral 
nervous system and in the absence of timely treatment 
this will lead to irreversible neuropathy in a large 
proportion of cases. This in turn leads to secondary 
impairments, such as wounds caused by burns or 
pressure on the sole of the foot, contractures of fingers 
and toes and visual impairment. These impairments can 
finally lead to limitations in activities of daily living 
and/or restrictions in social participation3. Leprosy is 
thereby a leading cause of preventable disability in 
India and poses a major public health challenge for the 
country.
 Although we have some grasp of the extent of 
the leprosy disability problem in India in terms of 
individuals affected, it is very difficult to establish the 
burden of this problem accurately. This is partly due to 
the inherent difficulty of measuring phenomena such 
as impairment, activities of daily living, stigma, social 
participation and quality of life. Such information 
is essential for planning services for prevention of 
disability and rehabilitation. Leprosy control worldwide 
has relied basically on the WHO Disability Grading 
system for measuring and reporting the disability 
burden in leprosy4. This is a leprosy-specific measure 
of severity of impairment of eyes, hands and feet, 
which can be established easily in field conditions. It 
has proven useful as a proxy indicator for the success 
of leprosy control in general. In leprosy control, early 
diagnosis and treatment are essential in preventing 
ongoing transmission of Mycobacterium leprae, 
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the causative agent of leprosy, as well as preventing 
the occurrence of permanent nerve damage. A low 
proportion of newly detected leprosy cases with grade 
2 disability is, therefore, an indicator of a successful 
control programme (new patients are apparently found 
in time), but does not provide much information 
on actual health burden, both at the individual and 
population levels. More recently, instruments have 
been developed for persons affected by leprosy to 
measure level of activity (e.g. the SALSA Scale5) and 
participation (e.g. the Participation Scale6). These 
newer approaches and tools for measuring disability 
in low and middle-income countries have been 
described comprehensively by Van Brakel & Officer7 
and represent important improvements in establishing 
the disability burden in people affected by leprosy and 
comparable diseases causing disability.
 For measuring disease burden at population level, a 
standard unit has been developed, namely the disability-
adjusted life years (DALY). This measure is useful for 
establishing (cost) effectiveness of interventions for 
preventing illness or alleviating disease burden. This 
measure has been widely used, also for estimating 
the burden of neglected tropical diseases, a category 
including leprosy8. DALY is the sum of years of life 
lost (YLL) plus years lost due to disability (YLD). 
Mortality in leprosy is not an important issue; a few 
people die from leprosy9. Therefore, the DALY in 
leprosy is derived primarily from YLD, which is the 
number of incident cases times disability weight times 
the average duration of the case until remission or death 
(in years). The average disability weight attributed to 
leprosy WHO Disability Grades 1 and 2 is 0.1528. 
In comparison, the disability weight for blindness is 
0.600. It is however, very difficult to measure disability 
caused by leprosy and its duration accurately. Disability 
often starts insidiously at a relatively early age and can 
develop gradually over time. DALY is, therefore, a 
problematic indicator to describe the burden of leprosy 
disease. 
 Rao and colleagues in their article in this issue10 
are commended for developing an alternative indicator 
to measure the leprosy burden; the disability adjusted 
working life years (DAWLY). It takes into account loss 
of (anticipated) productive work years, a meaningful 
economic indicator for both the individual and society. 
They showed a reduction of 13.4 years from the ideal 
productive working life period of 42 years. As the 
authors state correctly, the DAWLY as indicator needs 
refinement and further validation, but the concept is 
appealing because it is practical and easy to understand. 
In order to face the public health challenge of disability 
burden due to leprosy in India, it is essential to have 
suitable indicators and measurement tools to establish 
the burden of disability accurately in all its aspects, 
including physical impairments, activity limitation, and 
participation restriction. Knowledge of these factors 
will help developing effective preventive and support 
programmes and evaluating progress of these activities 
at individual and population levels. The DAWLY is an 
innovative contribution towards these ends.
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